In what could be a big win for the pharmaceutical industry, legislation is close to being signed into law in New York State that would absolve drug makers from paying for so-called drug take-back programs.

Identical bills recently passed the state Senate and Assembly that would, instead, require chain pharmacies to cover the costs, a move that bucks a growing trend on the West Coast, where drug makers have increasingly been forced by local governments to pay for these programs.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy